VascoStim B 2/5F is a bipolar temporary pacing lead with a balloon. It can be placed easily by the resistance of the inflated balloon in the blood flow.
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs.
The Aescula LV left-heart lead is a stylet-driven, silicone insulated lead with a titanium nitride (TiN) coated platinum-iridium electrode.
The Petite leads are low profile (4.8F lead body diameter) implantable endocardial pacing leads which are manufactured using a new proprietary hexafilar coil for permanent stimulation of the ventricl
Medicine Products:(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3(Date:9/3/2008)...ge of Rheumatology Research and Education Foundati... Advances in Detecting, Treati...wire/ -- For the first time during its,unprecedent...tis, the,American College of Rheumatology Research...tion acquired from research funded by the Within O...
(Date:9/3/2008)... is National Vascular Disease Awareness Month, CH...ion Pharmaceuticals,LLC, a clinical-stage drug-dev... treatment of unmet medical needs, announced today.../II clinical trial of its lead drug,candidate tran...NCT00725881,on the clinicaltrials.gov Website, is ...
(Date:9/3/2008)...., Sept. 3 /- Panacea Pharmaceuticals... Number 7,413,737 covering,antibodies against huma...a,proprietary human cancer biomarker and therapeut...aboration with the Massachusetts Institute of,Tech...rights to this patent,for development of human can...
(Date:9/3/2008)...pany to Discuss Phase 3 Plans with FDA, PRINCETON..., Inc.,announced today that it successfully compl... the company,s new, innovative low-dose, once-week...to by its internal product,code AG-200-15. The Pha...ts,primary endpoint of ovulation suppression, cycl...
Breaking Medicine Technology:New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4LeMaitre Vascular Appoints Russell D Hays to Its Board of Directors 2247 1LeMaitre Vascular Appoints Russell D Hays to Its Board of Directors 2247 2Research Reveals How Cells Store Fat 8416 1Research Reveals How Cells Store Fat 8416 2Research Reveals How Cells Store Fat 8416 3MIT works toward engineered blood vessels 1630 1MIT works toward engineered blood vessels 1630 2VH1 Set to Continue Its Record Breaking Pace Into 2008 with Brand New Premieres and Returning Series 8409 1VH1 Set to Continue Its Record Breaking Pace Into 2008 with Brand New Premieres and Returning Series 8409 2VH1 Set to Continue Its Record Breaking Pace Into 2008 with Brand New Premieres and Returning Series 8409 3VH1 Set to Continue Its Record Breaking Pace Into 2008 with Brand New Premieres and Returning Series 8409 4...linical Trials Initiated, CRANBURY, N.J., March 21...harmaceutical company developing small,molecule, o...the,treatment of a range of human genetic diseases...sults from its recently completed,Phase 1 clinical...101) for Gaucher disease at the of Medical Genetic...
...LD, N.J., March 22, 2007 /PRNewswire-FirstCall/ --... studies show mild,hyperthermia enhances the thera...ny,s lead investigational drug,candidate. , In a p...r cells,to undergo apoptosis upon treatment with O...f Oncology (April 2007), the studies,conducted by ...
Other Medicine Technology:Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease 2Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease 3Studies Show Mild Hyperthermia Enhances Antitumor Effects of,Alfacell's Onconase 2Studies Show Mild Hyperthermia Enhances Antitumor Effects of,Alfacell's Onconase 3